title: Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
abstract: Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.
authors.affiliation: Inviragen, Inc, Madison, 6502 Odana Rd, Madison, WI 53719, USA. hpartidos@inviragen.com
authors.forename: Charalambos D
authors.initials: CD
authors.lastname: Partidos
authors.forename: Joanna
authors.initials: J
authors.lastname: Paykel
authors.forename: James
authors.initials: J
authors.lastname: Weger
authors.forename: Erin M
authors.initials: EM
authors.lastname: Borland
authors.forename: Ann M
authors.initials: AM
authors.lastname: Powers
authors.forename: Robert
authors.initials: R
authors.lastname: Seymour
authors.forename: Scott C
authors.initials: SC
authors.lastname: Weaver
authors.forename: Dan T
authors.initials: DT
authors.lastname: Stinchcomb
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Osorio
mesh_terms: D018354:Alphavirus Infections / Q000517:prevention & control*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002646:Chikungunya virus / Q000276:immunology*; D056738:Cross Protection; D005260:Female; D007116:Immunization, Passive; D008297:Male; D051379:Mice; D009500:Neutralization Tests; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D010948:Viral Plaque Assay; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines